Form 4: Precigen CEO Acquires 1,803,000 Stock Options

Helen Sabzevari, President and CEO of Precigen, Inc., acquired 1,803,000 stock options on May 31, 2024, according to a Form 4 filing with the SEC.

Summary

• Helen Sabzevari, the President and CEO of Precigen, Inc. (PGEN), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 31, 2024.
• Sabzevari acquired 1,803,000 options to purchase common stock at an exercise price of $1.40.
• The options vest 25% on May 31, 2025, and the remainder vests in equal monthly installments over the following three years.
• The options expire on May 31, 2034.
• Following the reported transaction, Sabzevari directly owns 1,803,000 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates the CEO's belief in the company's future, but it's a standard practice.

Positives

• The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry. It reflects standard practice for aligning executive incentives with shareholder value.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation packages.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The granting of stock options to the CEO aligns her interests with those of the shareholders, potentially incentivizing her to increase shareholder value.

Key Dates